Non-human primate data sending Junshi, Lilly COVID-19 mAb to clinic

A Chinese Academy of Sciences team has provided evidence showing a mAb against SARS-CoV-2 from Lilly and Junshi is effective in monkeys -- a first for any COVID-19 mAb, according to the researchers -- and compares favorably on potency with other mAbs poised to enter the clinic.

The candidate appears to be at least as potent as other recently described SARS-CoV-2 mAbs -- including the one behind a pair of candidates from Vir Biotechnology Inc. (NASDAQ:VIR) -- although firm conclusions cannot be made due to variations in neutralization assay protocols...